To Get More Information on Human Insulin Market - Request Sample Report
The Human Insulin Market size was valued at USD 18.1 billion in 2023 and is expected to reach USD 24.6 billion by 2032 and grow at a CAGR of 3.4% over the forecast period of 2024-2032.
Revolutionary growth in the market is experienced in human insulin, mainly due to the increase in the prevalence of diabetes and regulatory developments that make the treatment more accessible. According to IDF data, as many as 537 million people in the world are suffering from the disease, and by 2045, this number will increase to 643 million. This increase in diabetic patients, driven by sedentary lifestyles, is fueling the rising demand for insulin products that are vital in the treatment of diabetes. In developed countries, positive reimbursement scenarios also bolster the market.
One of the most crucial developments affecting the human insulin market is that the U.S., under the Inflation Reduction Act, has taken a major initiative to establish the Medicare Drug Price Negotiation Program. This bill empowers Medicare to negotiate directly with pharmaceutical companies over the open market price of prescription drugs, knocking a significant amount off the cost of insulin for millions of Americans. This reform models extant practices by other federal agencies, such as the U.S. Department of Veterans Affairs, and represents a landmark shift in health policy.
More importantly, the biosimilar insulins are entering the market. For instance, Eli Lilly and Company launched an interchangeable biosimilar of insulin glargine called Rezvoglar at a 78% lower price than Lantus. Accepted by the FDA in 2021 and approved as interchangeable in 2022, Rezvoglar will be another drug that will contribute to market competition and reduce the cost of treatment. Another one of its classes, Biocon Biologic's Semglee, approved in 2021, intensifies the competition even more. Semglee is substitutable, so pharmacists can substitute Lantus with this drug without the physician's prescription, which is a big success factor in increasing the availability of insulin.
The threats include: Insulin being expensive, and new diabetes drugs such as GLP-1 receptor agonists, that can threaten the present market. However, innovation will keep going on, and long-term growth is expected from biosimilars, where the company giant Eli Lilly, Novo Nordisk, and Sanofi will dominate market share.
| Company | Key Products | Product Type | Market Positioning | Recent Developments | |
|---|---|---|---|---|---|
| Novo Nordisk | - NovoLog (insulin aspart) | Rapid-acting insulin | Market leader with strong brand recognition | Launched generic versions of NovoLog | |
| - Levemir (insulin detemir) | Long-acting insulin | Focus on innovative insulin therapies | Increased availability in emerging markets | ||
| - Tresiba (insulin degludec) | Long-acting insulin | Targeting personalized diabetes management | |||
| Eli Lilly | - Humalog (insulin lispro) | Rapid-acting insulin | Pioneered rapid-acting insulin formulations | Launched Lyumjev, a new human insulin analog in China | |
| - Basaglar (insulin glargine) | Long-acting insulin | Focus on cost-effective alternatives | Strategic partnerships to enhance market presence | ||
| Sanofi | - Lantus (insulin glargine) | Long-acting insulin | Strong foothold in global markets | Launched a new formulation of Lantus in India | |
| - Admelog (insulin lispro) | Rapid-acting insulin | Focus on affordable options | Collaborations with healthcare providers | ||
| Boehringer Ingelheim | - biosimilar insulin products (e.g., Semglee) | Biosimilar insulin | Focus on biosimilars to enhance patient access | Expanding portfolio of biosimilar insulin products | |
| - Vials and pens for diabetes management | Various | Strengthening R&D capabilities for diabetes treatment | Increased investment in research initiatives | ||
| Biocon Biologics | - Insulin human (various formulations) | Human insulin | Affordable insulin solutions in emerging markets | Secured a $90 million contract with the Malaysian government | |
| - biosimilar insulins | Biosimilar insulin | Focus on expanding market access | Launching new products in various regions | ||
Drivers
A strong increase in the prevalence of diabetes is expected to foster market growth.
The rise in diabetes worldwide, primarily linked to obesity and sedentary lifestyles, is a significant driver of the growth of the human insulin market. World Health Organization declares that half a million people die each year due to the non-communicable disease NCD diabetes alone. Despite all the preventive measures, type 2 diabetes is considered to be among the biggest challenges for healthcare systems in all countries. According to data from the IDF Diabetes Atlas (2021), the number of patients with diabetes worldwide will increase to 643 million by 2030 and to 783 million by 2045. In addition, millions of people around the world suffer from type 1 diabetes and require insulin therapy to regulate glycemia. As per the European Association for the Study of Diabetes (EASD), over 9 million people worldwide currently suffer from type 1 diabetes. Moreover, the International Diabetes Federation estimates that about 10% of all diabetic patients are affected by type 1 diabetes. As this type of diabetes is increasingly growing, the high demand for human insulin globally will continue to support market growth throughout the forecast period.
Launch of Novel Insulin Products Drives Expansion
A rise in the launch of new insulin-based products also provides impetus to the human insulin market. Companies in the pharmaceutical industry have been surging in the development of new kinds of insulin solutions to maximize market shares, thus helping the market gain momentum. For instance, Sanofi introduced Soliqua, a long-acting insulin, into the Indian market after receiving the approval of the Central Drugs Standard Control Organization (CDSCO) in March 2023. Similarly, Eli Lilly and Company received approval for Mounjaro used in the treatment of type 2 diabetes in May 2022 while Lyumjev as rapid-acting insulin used in the treatment of both type 1 and 2 diabetes, got approval in June 2020. The launches of such products shall be raising the human insulin market by considerable margins.
More research and development is needed and will enhance the market for new products, such as oral insulin delivery technology that will eventually offer alternative options to insulin pens. An example of this is in the study of oral insulin using nano-carrier delivery technology. This could be the most significant shift in insulin administration to date, and further development is set to propel growth in the market in the coming years.
Restraints
Lack of Health Reimbursement and Low Diagnosis Rates in Emerging Markets Hinder Growth
By Type
Analogue insulin dominated the market in 2023 with a 54.6% share due to its numerous advantages in comparison with traditional human insulin. Various studies and reports show that analog insulin has improved compliance with therapy and glycemic control with a reduced risk of hypoglycemia when compared with conventional insulin. According to Diabetes.co.uk, analog insulin is also a faster-acting and more consistent type of insulin, giving it an added impetus over the years.
More importantly, generic versions of products in the insulin category have further pushed up the growth in this segment. For instance, recently, the world's largest maker of insulin, Novo Nordisk A/S, said it would sell generic versions of NovoLog and NovoLog Mix, which are considerably cheaper than their branded counterparts.
This is because of low penetration in this segment. Compared to others, CAGR in the traditional human insulin segment will be slower due to this segment's lower adoption rate. With several traditional insulins including intermediate-acting insulin, there has been an increased trend wherein more healthcare providers prefer analogue insulin drugs because of higher effectiveness and better response from patients. This will further continue the dominance of analogue insulin in the market.
By Diabetes Type
In the year 2023, the type 1 diabetes segment grabbed the largest market share, which stood at 57.8% because of the increasing incidences of diabetes and the fact that patients suffering from type 1 diabetes need to rely on a daily dose of insulin shots to maintain blood glucose levels. As claimed by the IDF, for patients with type 1 diabetes, insulin is the most crucial medication.
In contrast, the type 2 diabetes segment is expected to grow at a lower CAGR than that for type 1; the primary reason is the existence of alternative treatments to manage type 2 diabetes. Patients having type 2 diabetes are prescribed human insulin only if other treatments fail. Nonetheless, the worldwide risk of developing type 2 diabetes is substantial. According to the IDF, 541 million adults suffer from IGT, a condition that predisposes them to type 2 diabetes. Therefore, though growth in the type 2 diabetes segment will be continuous, its rate will be slower compared with that of type 1 diabetes.
By Distribution Channel
The retail and online pharmacy segment stood at 59.2% of insulin revenues in 2023, mainly due to entrance by bigger players such as Amazon and Walmart. These entities have launched more affordable insulin options that have made insulin products more accessible. For instance, in June 2021, Walmart launched the brand ReliOn, an analog insulin available in vial and pen format. It costs between 58% to 75% cheaper than the alternative forms of branded insulin. In the same year, in November 2020 Amazon Pharmacy also began to sell and dispense insulin. More customers begin buying their insulin from the website due to the corporation.
The hospital pharmacy segment will see moderate CAGR, primarily fueled by global development in hospital infrastructure. Steady growth will be instead supported by increased availability of insulin in hospitals, though retail and online pharmacies are expected to continue dominating revenue markets.
North America generated a revenue share of 46.3% in the year 2023, thereby holding the largest share in the global market of human insulin. Contributive factors could be the strong presence of leading insulin manufacturers, healthy competition in the market, and the rising prevalence of type 1 diabetes in the region. According to the American Diabetes Association, 1.6 million Americans suffer from type 1 diabetes, including 187,000 children and adolescents. It is also worth mentioning that the increasing price of insulin in the U.S. during the last decade has enabled North America to gain a significant market share across the globe. According to the direct medical costs related to diabetes in the United States, the Centers for Disease Control and Prevention (CDC) consider that it reaches approximately USD 237 billion annually. Moreover, the "evergreening" of insulin products by major players in the market has enabled the firms to maintain substantial market share. For instance, the use of a CGM or an insulin pump reached about 30% penetration in the U.S. in 2021, according to Industry Dive.
Europe is expected to be the second-most lucrative market in terms of revenue, due to the growing availability of market leaders in the region. For instance, Sanofi began selling its next-generation basal insulin, Toujeo Solostar, to countries across the European Union in September 2021. Other growth in the latter half is also being aided by the formation of a more developed healthcare infrastructure and rising support for insulin therapies.
Asia Pacific is expected to grow at the highest compound annual growth rate (CAGR) during the forecast period. This is mainly due to the risk factors of diabetes development within the region, with its high risk among elderly populations in its respective locales. The Asian Diabetes Prevention Initiative states that lifestyle and dietary trends in Asia, such as smoking, poor diet, and physical inactivity, have a high risk of developing diabetes. This factor, with increasing healthcare awareness and widening access to insulin products, shall only fuel further growth in the Asian Pacific market.
Do You Need any Customization Research on Human Insulin Market - Enquire Now
Sanofi
Oramed
Eli Lilly and Company
Biocon
Julphar
BIOTON S.A.
Pfizer Inc.
Gan & Lee Pharmaceuticals
Bristol-Myers Squibb Company
GlaxoSmithKline Plc
Wockhardt
Tonghua Dongbao Pharmaceutical Co., Ltd., and others.
Nov 2023: Biocon Biologics Secures USD 90 million Contract with the Government of Malaysia in the Human Insulin Business. Biocon Biologics biosimilars arm of Biocon- is setting a new benchmark in the Insulin business as it has bagged its largest contract with the Malaysian government to supply human insulin valued at USD 90 million. The five-year deal starting in 2024 is the largest that Biocon Biologics has signed for its insulin portfolio.
October 2023: Eli Lilly Launches New Rapid-Acting Human Insulin Analog in China. Eli Lilly and Company has launched Lyumjev, a rapid-acting human insulin analog for the treatment of diabetes, in China. Lyumjev is designed to start working much faster than other insulin products; it provides an effective solution for individuals suffering from diabetes who need to regulate blood sugar levels post-meal.
Sept. 2023: Novo Nordisk to Halve Prices of Human Insulin in Low- and Middle-Income Countries. The company said it will cut prices of its human insulin brands by as much as 50% in low- and middle-income countries, where three of four people with diabetes live.
August 2023: Sanofi Introduces Human Insulin Formulation in India. Sanofi recently unveiled a new formulation of its human insulin product in India. The company announced the new formulation of the human insulin product, Lantus, which provides better stability and easier administration to patients.
| Report Attributes | Details |
| Market Size in 2023 | US$ 18.1 billion |
| Market Size by 2032 | US$ 24.6 billion |
| CAGR | CAGR of 3.4% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Analogue Insulin, Traditional Human Insulin) • By Diabetes Type (Diabetes Type 1, Diabetes Type 2) • By Distribution Channel (Hospital Pharmacies, Retail & Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe [Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Sanofi, Oramed, Adocia, Merck & Co.Inc, Novo Nordisk A/S, Eli Lilly and Company, Biocon, Julphar, BIOTON S.A., Pfizer Inc., Gan & Lee Pharmaceuticals , Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Wockhardt, Tonghua Dongbao Pharmaceutical Co., Ltd., and others. |
| Key Drivers | • A strong increase in the prevalence of diabetes is expected to foster market growth. • Launch of Novel Insulin Products Drives Expansion |
| Market Restraints | • Lack of Health Reimbursement and Low Diagnosis Rates in Emerging Markets Hinder Growth |
Ans: The Human Insulin Market is to grow at 3.4% Over the Forecast Period 2024-2032.
Ans: The projected market size of the Human Insulin Market is hit USD 24.6 billion by 2032.
Ans: Novo Nordisk, Companion Medical Inc., Valeritas Inc., Emperra Gmbh E-Health Technologies, Cellenovo, Insulet Corporation, F Hoffmann-La Roche, Medronic Inc., Tandem Diabetes Care, and Ypsomed.
Ans: In 2023, analogue insulin controlled the market.
Ans: At the moment, North America controls the world market for human insulin.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Cancer, by Type (2023)
5.2 Adoption Trends of Liquid and Tissue Biopsy Techniques, by Region (2023)
5.3 Volume of Human Insulin Procedures, by Region (2020-2032)
5.4 Healthcare Spending on Cancer Biopsies, by Region (Government, Commercial, Private, Out-of-Pocket), 2023
5.5 Trends in Human Insulin Technology and Innovation (2023)
5.6 Regulatory Approvals and Guidelines for Human Insulin Devices and Methods (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Human Insulin Market Segmentation, by Type
7.1 Chapter Overview
7.2 Analogue Insulin
7.2.1 Analogue Insulin Market Trends Analysis (2020-2032)
7.2.2 Analogue Insulin Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Long-acting
7.2.3.1 Long-acting Market Trends Analysis (2020-2032)
7.2.3.2 Long-acting Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Fast-acting
7.2.4.1 Fast-acting Market Trends Analysis (2020-2032)
7.2.4.2 Fast-acting Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.5 Premix
7.2.5.1 Premix Market Trends Analysis (2020-2032)
7.2.5.2 Premix Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Traditional Human Insulin
7.3.1 Traditional Human Insulin Market Trends Analysis (2020-2032)
7.3.2 Traditional Human Insulin Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.3 Long-acting
7.3.3.1 Long-acting Market Trends Analysis (2020-2032)
7.3.3.2 Long-acting Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.4 Short-acting
7.3.4.1 Short-acting Market Trends Analysis (2020-2032)
7.3.4.2 Short-acting Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.5 Fast-acting
7.3.5.1 Fast-acting Market Trends Analysis (2020-2032)
7.3.5.2 Fast-acting Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3.6 Premix
7.3.6.1 Premix Market Trends Analysis (2020-2032)
7.3.6.2 Premix Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Human Insulin Market Segmentation, by Diabetes Type
8.1 Chapter Overview
8.2 Diabetes Type 1
8.2.1 Diabetes Type 1 Market Trends Analysis (2020-2032)
8.2.2 Diabetes Type 1 Market Size Estimates and Forecasts to 2032 (USD Million)
8.2.3 Diabetes Type 2
8.2.3.1 Diabetes Type 2 Market Trends Analysis (2020-2032)
8.2.3.2 Diabetes Type 2 Market Size Estimates and Forecasts to 2032 (USD Million)
9. Human Insulin Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Retail & Online Pharmacies
9.3.1 Retail & Online Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Retail & Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.4 North America Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.2.5 North America Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.6.2 USA Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.2.6.3 USA Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.7.2 Canada Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.2.7.3 Canada Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.8.2 Mexico Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.2.8.3 Mexico Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.6.2 Poland Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.6.3 Poland Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.7.2 Romania Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.7.3 Romania Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.8.2 Hungary Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.8.3 Hungary Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.9.2 Turkey Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.9.3 Turkey Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.4 Western Europe Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.5 Western Europe Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.6.2 Germany Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.6.3 Germany Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.7.2 France Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.7.3 France Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.8.2 UK Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.8.3 UK Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.9.2 Italy Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.9.3 Italy Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.10.2 Spain Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.10.3 Spain Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.13.2 Austria Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.13.3 Austria Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.4 Asia Pacific Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.5 Asia Pacific Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.6.2 China Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.6.3 China Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.7.2 India Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.7.3 India Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.8.2 Japan Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.8.3 Japan Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.9.2 South Korea Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.9.3 South Korea Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.10.2 Vietnam Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.10.3 Vietnam Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.11.2 Singapore Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.11.3 Singapore Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.12.2 Australia Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.12.3 Australia Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.4 Middle East Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.5 Middle East Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.6.2 UAE Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.6.3 UAE Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.7.2 Egypt Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.7.3 Egypt Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.9.2 Qatar Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.9.3 Qatar Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.4 Africa Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.2.5 Africa Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.6.2 South Africa Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.2.6.3 South Africa Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Human Insulin Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.4 Latin America Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.6.5 Latin America Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.6.2 Brazil Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.6.6.3 Brazil Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.7.2 Argentina Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.6.7.3 Argentina Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.8.2 Colombia Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.6.8.3 Colombia Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Human Insulin Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Human Insulin Market Estimates and Forecasts, by Diabetes Type (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Human Insulin Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Million)
11. Company Profiles
11.1 Sanofi
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Oramed
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Merck & Co.Inc
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Julphar
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Pfizer Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Gan & Lee Pharmaceuticals
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 GlaxoSmithKline Plc
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Bristol-Myers Squibb Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Wockhardt
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Type
Analogue Insulin
Long-acting
Fast-acting
Premix
Traditional Human Insulin
Long-acting
Short-acting
Fast-acting
Premix
By Diabetes Type
Diabetes Type 1
Diabetes Type 2
By Distribution Channel
Hospital Pharmacies
Retail & Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Nasal Drug Delivery Market was estimated at USD 76.85 billion in 2023 and is poised to reach 137.06 billion in 2031 anticipated to expand at a compound annual growth rate approx. CAGR of 7.5% for the forecast period of 2024-2031.
The Cone Beam Computer Tomography (CBCT) Market Size was valued at USD 541.93 million in 2023, and is expected to reach USD 1342.77 million by 2031, and grow at a CAGR of 12.01% over the forecast period 2024-2031.
The Scaffold Technology Market was valued at USD 1.88 Bn in 2023 and is expected to reach USD 6.05 Bn by 2032 and grow at a CAGR of 13.82% Over the Forecast period of 2024-2032.
The Urinary Drainage Bags Market size was valued at USD 2.12 billion in 2023 and will reach USD 3.13 billion by 2031 & growing at a CAGR of 5% by 2024-2031.
The Digital Radiology Market was estimated at USD 3.8 billion in 2023 and is projected to reach USD 5.04 billion by 2031, developing at a CAGR of 3.6% from 2024 to 2031.
The Hemostats Market Size was valued at USD 2.8 billion in 2023, and is expected to reach USD 5.06 billion by 2032, and grow at a CAGR of 6.8% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
